Inhibition of the ERK phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells

Toxicology and Applied Pharmacology

Volumn 229, Issue 1, 2008, Pages 86-93

  Ho, Pei Yin ^a   Hsu, Sung Po ^b   Liang, Yu Chih ^a   Kuo, Min Liang ^b   Ho, Yuan Soon ^a   Lee, Wen Sen ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

DNA synthesis; ERK; p21; p53; Terbinafine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; FARNESOL; GERANYLGERANIOL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P21; RAS PROTEIN; TERBINAFINE; THYMIDINE;

ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NAPHTHALENES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL VEINS; UP-REGULATION;

EID: 42749091148     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.12.028     Document Type: Article

References (41)

1. Abdel-Rahman S.M., and Nahata M.C. Oral terbinafine: a new antifungal agent. Ann. Pharmacother. 31 (1997) 445-456
2. Arkell J., and Jackson C.J. Constitutive secretion of MMP9 by early-passage cultured human endothelial cells. Cell Biochem. Funct. 21 (2003) 381-386
3. Bussolino F., Mantovani A., and Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22 (1997) 251-256
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
5. Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F., and Chen R.H. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J. 24 (2005) 294-304
6. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem. 91 (2004) 223-231
7. Edamatsu H., Gau C.L., Nemoto T., Guo L., and Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19 (2000) 3059-3068
8. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
9. Feldkamp M.M., Lau N., and Guha A. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities. Ann. N.Y. Acad. Sci. 886 (1999) 257-260
10. Gupta A.K., and Shear N.H. Terbinafine: an update. J. Am. Acad. Dermatol. 37 (1997) 979-988
11. Gupta M.K., and Qin R.Y. Mechanism and its regulation of tumor-induced angiogenesis. World J. Gastroenterol. 9 (2003) 1144-1155
12. Gupta A.K., del Rosso J.Q., Lynde C.W., Brown G.H., and Shear N.H. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin. Exp. Dermatol. 23 (1998) 64-67
13. Ho P.Y., Liang Y.C., Ho Y.S., Chen C.T., and Lee W.S. Inhibition of human vascular endothelial cells proliferation by terbinafine. Int. J. Cancer 111 (2004) 51-59
14. Ho P.Y., Zhong W.B., Ho Y.S., and Lee W.S. Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway. Mol. Cancer Ther. 5 (2006) 3130-3138
15. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino K., Ikeda E., Takata S., Kobayashi K., and Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16 (2002) 219-221
16. Jerry D.J., Dickinson E.S., Roberts A.L., and Said T.K. Regulation of apoptosis during mammary involution by the p53 tumor suppressor gene. J. Dairy Sci. 85 (2002) 1103-1110
17. Kim S.J., Ju J.W., Oh C.D., Yoon Y.M., Song W.K., Kim J.H., Yoo Y.J., Bang O.S., Kang S.S., and Chun J.S. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J. Biol. Chem. 277 (2002) 1332-1339
18. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351 Pt 2 (2000) 289-305
19. Kwon Y.W., Kwon K.S., Moon H.E., Park J.A., Choi K.S., Kim Y.S., Jang H.S., Oh C.K., Lee Y.M., Kwon Y.G., Lee Y.S., and Kim K.W. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J. Invest. Dermatol. 123 (2004) 152-158
20. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
21. Lee W.S., Chen R.J., Wang Y.J., Tseng H., Jeng J.H., Lin S.Y., Liang Y.C., Chen C.H., Lin C.H., Lin J.K., Ho P.Y., Chu J.S., Ho W.L., Chen L.C., and Ho Y.S. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest. Int. J. Cancer 106 (2003) 125-137
22. Lee S.K., Kim J.M., Lee M.Y., Son K.H., Yeom Y.I., Kim C.H., Shin Y., Koh J.S., Han D.C., and Kwon B.M. Confirmation of a linkage between H-Ras and MMP-13 expression as well as MMP-9 by chemical genomic approach. Int. J. Cancer 118 (2006) 2172-2181
23. Liang Y.C., Huang Y.T., Tsai S.H., Lin-Shiau S.Y., Chen C.F., and Lin J.K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20 (1999) 1945-1952
24. Lin S.Y., Liu J.D., Chang H.C., Yeh S.D., Lin C.H., and Lee W.S. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J. Cell. Biochem. 84 (2002) 532-544
25. Magee T., and Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell 98 (1999) 9-12
26. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., and Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
27. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C.A., Dalla Palma P., and Bevilacqua G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12 (1996) 1319-1324
28. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
29. Mendoza-Rodriguez C.A., and Cerbon M.A. Tumor suppressor gene p53: mechanisms of action in cell proliferation and death. Rev. Invest. Clin. 53 (2001) 266-273
30. Moraes J.R., and Stastny P. A new antigen system expressed in human endothelial cells. J. Clin. Invest. 60 (1977) 449-454
31. Nakagami H., Morishita R., Yamamoto K., Taniyama Y., Aoki M., Kim S., Matsumoto K., Nakamura T., Higaki J., and Ogihara T. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J. Hypertens. 18 (2000) 1411-1420
32. Nakagami H., Morishita R., Yamamoto K., Taniyama Y., Aoki M., Matsumoto K., Nakamura T., Kaneda Y., Horiuchi M., and Ogihara T. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37 (2001) 581-586
33. Okazaki K., and Sagata N. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10 (1995) 1149-1157
34. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., Pauly R.R., Grant D.S., and Martin G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67 (1992) 519-528
35. Petranyi G., Ryder N.S., and Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 224 (1984) 1239-1241
36. Sepp-Lorenzino L., and Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 273 (1998) 20243-20251
37. Uchima Y., Sawada T., Nishihara T., Maeda K., Ohira M., and Hirakawa K. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 29 (2004) 123-131
38. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
39. Wong K.B., DeDecker B.S., Freund S.M., Proctor M.R., Bycroft M., and Fersht A.R. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8438-8442
40. Yu J., and Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331 (2005) 851-858
41. Yuen P.H., Ryan E.A., Devroe E., and Wong P.K. A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7Delta447Gag-tMos protein causes the mutant virus to induce brain lesions. Oncogene 20 (2001) 692-703